These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 26987789

  • 1. Circadian variations in laboratory measurements of coagulation assays after administration of rivaroxaban or warfarin in patients with nonvalvular atrial fibrillation.
    Hitaka Y, Ogawa M, Zhang B, Goto S, Nagata Y, Morii J, Imaizumi S, Yasuda T, Matsumoto N, Matsunaga A, Saku K.
    J Cardiol; 2016 Dec; 68(6):529-535. PubMed ID: 26987789
    [Abstract] [Full Text] [Related]

  • 2. Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population.
    Kitagawa F, Ishii J, Hiramitsu S, Takahashi H, Okuyama R, Kawai H, Muramatsu T, Harada M, Motoyama S, Naruse H, Matsui S, Sarai M, Hayashi M, Watanabe E, Izawa H, Ozaki Y.
    Heart Vessels; 2017 May; 32(5):609-617. PubMed ID: 27796530
    [Abstract] [Full Text] [Related]

  • 3. Effect of rivaroxaban on prothrombin fragment 1+2 compared with warfarin in patients with acute cardioembolic stroke: Insight from its serial measurement.
    Hagii J, Tomita H, Metoki N, Tamai Y, Saito S, Shiroto H, Hitomi H, Kamada T, Seino S, Takahashi K, Sasaki S, Yasujima M, Okumura K.
    Thromb Res; 2016 Dec; 148():9-14. PubMed ID: 27764730
    [Abstract] [Full Text] [Related]

  • 4. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
    Hirano T, Kaneko H, Mishina S, Wang F, Morita S.
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
    [Abstract] [Full Text] [Related]

  • 5. Impact of rivaroxaban compared with warfarin on the coagulation status in Japanese patients with non-valvular atrial fibrillation: a preliminary analysis of the prothrombin fragment 1+2 levels.
    Tajiri K, Sato A, Harunari T, Shimojo N, Yamaguchi I, Aonuma K.
    J Cardiol; 2015 Mar; 65(3):191-6. PubMed ID: 25192595
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. D-Dimer versus International Normalized Ratio of Prothrombin Time in Ischemic Stroke Patients Treated with Sufficient Warfarin.
    Yamamoto R, Nakae Y, Tanaka F, Johkura K.
    J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1781-1785. PubMed ID: 27103270
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nonvalvular atrial fibrillation: evidence for a prothrombotic state.
    Kahn SR, Solymoss S, Flegel KM.
    CMAJ; 1997 Sep 15; 157(6):673-81. PubMed ID: 9307553
    [Abstract] [Full Text] [Related]

  • 10. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation.
    Nakamura A, Kuroda J, Ago T, Hata J, Matsuo R, Arakawa S, Kuwashiro T, Yasaka M, Okada Y, Kitazono T, Kamouchi M, Fukuoka Stroke Registry Investigators.
    Cerebrovasc Dis; 2016 Sep 15; 42(3-4):196-204. PubMed ID: 27111222
    [Abstract] [Full Text] [Related]

  • 11. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?
    Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.
    Curr Med Res Opin; 2014 Apr 15; 30(4):645-53. PubMed ID: 24256067
    [Abstract] [Full Text] [Related]

  • 12. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation.
    Koefoed BG, Feddersen C, Gulløv AL, Petersen P.
    Thromb Haemost; 1997 May 15; 77(5):845-8. PubMed ID: 9184390
    [Abstract] [Full Text] [Related]

  • 13. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
    Al-Aieshy F, Malmström RE, Antovic J, Pohanka A, Rönquist-Nii Y, Berndtsson M, Al-Khalili F, Skeppholm M.
    Eur J Clin Pharmacol; 2016 Jun 15; 72(6):671-9. PubMed ID: 27066956
    [Abstract] [Full Text] [Related]

  • 14. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Lingohr-Smith M, Menges B, Lin J.
    Curr Med Res Opin; 2017 Oct 15; 33(10):1745-1754. PubMed ID: 28849676
    [Abstract] [Full Text] [Related]

  • 15. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
    Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.
    Curr Med Res Opin; 2014 Aug 15; 30(8):1521-8. PubMed ID: 24758611
    [Abstract] [Full Text] [Related]

  • 16. Fiix-prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix-warfarin or direct oral anticoagulants to standard PT-warfarin.
    Onundarson PT, Arnar DO, Lund SH, Gudmundsdottir BR, Francis CW, Indridason OS.
    Int J Lab Hematol; 2016 May 15; 38 Suppl 1():78-90. PubMed ID: 27426862
    [Abstract] [Full Text] [Related]

  • 17. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.
    J Am Coll Cardiol; 2013 Feb 12; 61(6):651-8. PubMed ID: 23391196
    [Abstract] [Full Text] [Related]

  • 18. [Real life clinical management of nonvalvular atrial fibrillation: results from the Italian epidemiological survey eXperience on the use of rivaroxaban].
    Colonna P, Ammirati F, a nome del Gruppo Italiano eXperience.
    G Ital Cardiol (Rome); 2016 Nov 12; 17(11):932-939. PubMed ID: 27996999
    [Abstract] [Full Text] [Related]

  • 19. Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban.
    Nakano Y, Kondo T, Osanai H, Murase Y, Nakashima Y, Asano H, Ajioka M, Sakai K, Inden Y, Murohara T.
    J Cardiol; 2015 Mar 12; 65(3):185-90. PubMed ID: 25192594
    [Abstract] [Full Text] [Related]

  • 20. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
    Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.
    Adv Ther; 2015 Mar 12; 32(3):216-27. PubMed ID: 25784509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.